# A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

> **NCT01470118** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 127 (actual)

## Conditions studied

- Conjunctivitis, Allergic

## Interventions

- **DRUG:** alcaftadine 0.25% ophthalmic solution
- **DRUG:** olopatadine 0.2% ophthalmic solution
- **DRUG:** dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%

## Key facts

- **NCT ID:** NCT01470118
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2013-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470118, "A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01470118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*